Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United Sta…
$36.43+0.03%
报价 2026-11-06
市值
$1.45B
EV
$1.65B
PE (TTM)
103.2x
预期 PE (FY2026)
12.6x
52 周区间距高点 0.0%
$19.16$36.43
筛选结果
pipeline · 2026-11-06Filter✗ 高增长✗ Cheap✗ GARP
does not hit growth, cheap, or GARP pool
爆发潜力
2026-11-07未命中✗ 收入线✗ EPS 线
| 财年 | 收入倍数 | EPS | PE |
|---|---|---|---|
| FY+22027-12 | 1.1x | 2.62 → 3.46（1.3x） | 10.5 |
| FY+32028-12 | 1.2x | 2.62 → 4.61（1.8x） | 7.9 |
毛利率 79% · TTM 收入 $743M · 基数 EPS 2.62（调整后）
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| PCRXPacira BioSciences, Inc. | $1.45B | +0.0% | +3.3% | 77% | 103.2x | 14.4x | 8.1x | |
| KODKodiak Sciences Inc. | $6.24B | +9.1% | +1783.3% | 0% | – | – | – | |
| XNCRXencor, Inc. | $2.66B | +5.0% | +15.5% | 93.9% | – | – | – | |
| ANABAnaptysBio, Inc. | $1.39B | +1.9% | -48.8% | 99% | – | 27.8x | 68.4x | |
| CRONCronos Group Inc. | $1.33B | -3.0% | +53.8% | 53.7% | 18.4x | 14.9x | 25.6x | 高增长 |
| URGNUroGen Pharma Ltd. | $1.21B | -3.8% | +135.3% | 90.9% | – | – | – | |
| TNDMTandem Diabetes Care, Inc. | $1.18B | -6.0% | +7.1% | 56.9% | – | – | – | |
| OCSOculis Holding AG | $462.4M | +9.7% | – | -2,889.4% | – | – | – | |
| PHATPhathom Pharmaceuticals, Inc. | $426.8M | +3.3% | +91.4% | 87.1% | – | – | – | |
| 同行中位数 | – | – | +53.8% | 72% | 18.4x | 21.4x | 47.0x |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
| Metric | 2026-06-30 Q2 2026 | 2026-03-31 Q1 2026 | 2025-12-31 Q4 2025 | 2025-09-30 Q3 2025 | 2025-06-30 Q2 2025 | 2025-03-31 Q1 2025 | 2024-12-31 Q4 2024 | 2024-09-30 Q3 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $192.4M | $177.4M | $196.9M | $179.5M | $181.1M | $168.9M | $187.3M | $168.6M |
| Gross Margin | 77% | 79.5% | 79.5% | 80.9% | 77.4% | 79.7% | 78.7% | 76.9% |
| Operating Margin | 2.2% | 2.6% | 1.6% | 3.5% | 4.7% | 1.2% | 13.2% | -82.8% |
| Net Income | $4.7M | $2.9M | $1.6M | $5.4M | $-4.8M | $4.8M | $16M | $-143.5M |
| Diluted EPS | 0.12 | 0.07 | 0.04 | 0.12 | -0.11 | 0.1 | 0.34 | -3.11 |
| Operating Cash Flow | $57.5M | $25.7M | $43.7M | $60.8M | $12M | $35.5M | $33.1M | $53.9M |
研究材料
电话会纪要摘要
暂无纪要摘要。